Data Bytes: Thrive megaround pours more cash into early cancer detection

Thrive’s $257 million series B round continues a trend of investors seeing big value in liquid biopsy tests for early cancer detection, a stark contrast to the historic undervaluing of diagnostics.

Launched last year with a $110 million series A round led by Third Rock Ventures, Thrive Earlier Detection Corp. said the raise announced Wednesday will support a large, diverse registrational trial for its CancerSEEK blood test. The financing attracted 21 new and existing investors (see “Thrive to Make Case for Broad Access to CancerSEEK”)...